Cartesian Therapeutics, Inc. RNAC
Set alert
6.49 USD -0.26 -3.85%
At close · Oct 30
6.49 0.00 0.00%
After hours · Oct 30, 4:54 PM ET
6.44 Day range 6.76
5.84 52-week range 10.59
- YTD
- -9.99%
- 1 year
- -19.98%
- Open
- 6.72
- Prev close
- 6.75
- Mkt cap
- 196.36M
- Vol
- 78.80K
- Avg vol
- 131.43K
- EPS
- -5.78
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.44
- High
- 6.76
- Forward P/E
- -5.54
- Beta
- 0.00
- Short ratio
- 15.83
- Inst. own
- 27.85%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 20.18
- 200-d avg
- 19.88
- 1y target
- 38.17
6M chart
Signals (29)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| RSI: Oversold | Oct 16, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 5, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 25, 2026 | 1 month ago |
| SMA: Bearish | Sep 11, 2026 | 1 month ago |
| SMA: Bearish | Sep 8, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 1, 2026 | 2 months ago |
| RSI: Overbought | Aug 19, 2026 | 2 months ago |
| SMA: Bullish | Aug 6, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 6, 2026 | 2 months ago |
| SMA: Bullish | Jul 30, 2026 | 3 months ago |
| SMA: Bearish | Jul 29, 2026 | 3 months ago |
| SMA: Bearish | Jul 17, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 9, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 11, 2026 | 4 months ago |
| SMA: Bullish | Jun 10, 2026 | 4 months ago |
| SMA: Bullish | Jun 9, 2026 | 4 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| SMA: Bullish | May 28, 2026 | 5 months ago |
| SMA: Bullish | May 27, 2026 | 5 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| MACD: Sell Signal | May 18, 2026 | 5 months ago |
| SMA: Bullish | May 5, 2026 | 6 months ago |
| SMA: Bullish | May 4, 2026 | 6 months ago |
| MACD: Buy Signal | May 4, 2026 | 6 months ago |
| MACD: Sell Signal | May 1, 2026 | 6 months ago |
Key statistics
- Market cap
- 491.78M
- Enterprise value
- 278.84M
- Trailing P/E
- 0.00
- Forward P/E
- -5.54
- PEG ratio
- 0.00
- Price / sales
- 10.26
- Price / book
- 624.19
- EPS (TTM)
- -55.43
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 47.94M
- Revenue growth
- -94.10%
- Free cash flow
- -2.93M
- Total cash
- 219.20M
- Total debt
- 14.65M
- Return on equity
- -7029.26%
- Shares outstanding
- 25.41M
- Short % of float
- 11.47%
- 50-day average
- 20.18
- 200-day average
- 19.88
Analyst view
Consensus: buy
Buy
Price target (mean) 38.17 +488.1% upside
Now 6.49
- Target (low)
- 22.00
- Target (mean)
- 38.17
- Target (high)
- 45.00
Ratings (0m) 8 6 buy · 2 hold · 0 sell
- Strong buy2
- Buy4
- Hold2
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
RNAC Revenue — quarterly 0
RNAC Net income — quarterly 15.77M
RNAC EPS — quarterly 0.47
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.78 | -0.69 | +0.09 | +11.54% |
| Aug 8, 2024 | Jun 1, 2024 | -0.81 | 0.54 | +1.35 | +166.67% |
| May 8, 2024 | Mar 1, 2024 | -0.81 | -1.97 | -1.16 | -143.21% |
| Mar 7, 2024 | Dec 1, 2023 | -0.30 | -2.40 | -2.10 | -700.00% |
| Nov 13, 2023 | Sep 1, 2023 | -2.10 | -2.40 | -0.30 | -14.29% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 19, 2024 | BTIG | init | — | Buy |
| Dec 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 3, 2024 | Needham | reit | Buy | Buy |
| Nov 25, 2024 | Needham | reit | Buy | Buy |
| Nov 8, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 8, 2024 | Needham | reit | Buy | Buy |
About Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cartesiantherapeutics.com
News
- Cartesian: Maintaining 'Buy' On Descartes-08 MG Data Release And CAR-T Agreement
- Cartesian Therapeutics (NASDAQ:RNAC) versus Syndax Pharmaceuticals (NASDAQ:SNDX) Critical Comparison
- Cartesian Therapeutics Announces New Employment Inducement Grants
- HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $25 Price Target
- Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target
- Cartesian Therapeutics Presents Additional Retreatment Data Of Its Lead Investigational Asset, Descartes-08, In Patients With Generalized MG, During MGFA Scientific Session Of 2026 AANEM Annual Meeting
- Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis
- Cartesian Therapeutics Announces New Employment Inducement Grants
- Cartesian Therapeutics to Participate in Upcoming Investor Conferences
- Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target
Your note
Sign in to keep a note on RNAC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARABE TIMOTHY CRAIG | Director | Purchase | Aug 11, 2024 | 21,766 |
| HOGE ELIZABETH | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Oct 10, 2024 | 0 |
| JEWELL CHRISTOPHER M | Officer | Conversion of Exercise of derivative security | Nov 19, 2024 | 39,940 |
| KALAYOGLU MURAT | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Oct 10, 2024 | 0 |
| KURTOGLU METIN | Chief Technology Officer | Conversion of Exercise of derivative security | Dec 9, 2024 | 51,033 |
| MALIK KEMAL | Director | Stock Award(Grant) | Jun 30, 2024 | 5,933 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 11.22% | 2,851,830 | 55.18M | Sep 29, 2024 |
| MPM BioImpact Capital LLC | 2.48% | 629,423 | 12.18M | Sep 29, 2024 |
| Siren, L.L.C. | 2.25% | 572,236 | 11.07M | Sep 29, 2024 |
| Blackrock Inc. | 1.67% | 423,466 | 8.19M | Sep 29, 2024 |
| Citadel Advisors Llc | 1.48% | 375,767 | 7.27M | Sep 29, 2024 |
| JP Morgan Chase & Company | 1.22% | 309,018 | 5.98M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Select Portfolios - Biotechnology | 3.69% | 936,691 | 18.12M | Oct 30, 2024 |
| Fidelity Select Portfolios - Health Care | 1.45% | 368,992 | 7.14M | Oct 30, 2024 |
| Fidelity Growth Company Fund | 1.34% | 341,346 | 6.61M | Oct 30, 2024 |
| Fidelity Advisor Health Care Fund | 0.91% | 230,254 | 4.46M | Oct 30, 2024 |
| iShares Russell 2000 ETF | 0.70% | 177,734 | 3.44M | Oct 30, 2024 |
| Fidelity Advisor Biotechnology Fund | 0.66% | 167,950 | 3.25M | Oct 30, 2024 |